Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

To join this study, you would generally need to be an adult diagnosed with multiple myeloma that has either returned or not improved after your last treatment. Your overall health and ability to carry out daily activities should be good, often described as having an 'ECOG score of 0 or 1', meaning you are fully active or can do light tasks.

There are also specific requirements about your disease itself, like needing to have evidence of the multiple myeloma that can be measured by medical tests. This allows the researchers to track how well the treatment is working.

However, you wouldn't be able to join if you've already had treatment with etentamig or certain specific types of treatments that target a protein called BCMA. You also can't have taken iberdomide or a similar drug called mezigdomide before. These rules help make sure the study can properly test the new combination of drugs.

If you decide to take part in this study, you will need to attend regular appointments at a hospital or clinic. These visits are important for the study team to check your health, give you the study medication, and monitor how you are responding. You will receive etentamig through a drip into your vein (intravenously), and iberdomide will be taken by mouth.

Throughout the study, you'll have various medical checks, blood tests, and fill out questionnaires. These will help the study team keep track of your condition, look for any improvements, and carefully watch out for any side effects you might experience. The full study could last for approximately 129 months, so it is a significant long-term commitment.